Citations

Clear

2285 citation(s) found for "Yu, Anthony".

Specialized stellate cells offer a privileged route for rapid water flux in Drosophila renal tubule
Cabrero, Pablo , Terhzaz, Selim , Dornan, Anthony J. , Ghimire, Saurav , Holmes, Heather L. , Turin, Daniel R. , Romero, Michael F. , Davies, Shireen A. , Dow, Julian A. T. , Dow, Julian A T , Romero, Michael F

Mayo Clinic

Proceedings of the National Academy of Sciences | January 6, 2020 | Volume: 117 | Issue: 3 | Pages: 1779-1787

10.1073/pnas.1915943117 | PMID 31907321 Get It

Significance The tiny insect renal (Malpighian) tubule can transport fluid at unparalleled speed, suggesting unique specializations. Here we show that strategic allocation of major intrinsic proteins (MIPs) to specific cells within the tubule allows the separation of metabolically intense active cation transport from passive chloride and water conductance. This specialized renal architecture is general to at least many higher insects, providing a clue to the unique success of the class Insecta in colonizing an extraordinary range of ecological niches.
Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
Goyal, Namita , Windebank, Anthony J. , Staff, Nathan P. , Maragakis, Nicholas J. , Berg, Leonard H. van den , Genge, Angela , Baloh, Robert H. , Kern, R. , Gothelf, Yaël, Lebovits, Chaim, Cudkowicz, Merit , Windebank, Anthony, Staff, Nathan P , Maragakis, Nicholas , Cudkowicz, Merit E , Berry, James D. , Miller, Robert G.

Mayo Clinic

Muscle & Nerve | January 3, 2020 | Volume: 62 | Issue: 2 | Pages: 156-166

10.1002/mus.26801 | PMID 31899540 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder with complex biology and significant clinical heterogeneity. Many preclinical and early phase ALS clinical trials have yielded promising results that could not be replicated in larger phase 3 confirmatory trials. One reason for the lack of reproducibility may be ALS biological and clinical heterogeneity. Therefore, in this review, we explore sources of ALS heterogeneity that may reduce statistical power to evaluate efficacy in ALS trials. We also review efforts to manage clinical heterogeneity, including use of validated disease outcome measures, predictive biomarkers of disease progression, and individual clinical risk stratification. We propose that personalized prognostic models with use of predictive biomarkers may identify patients with ALS for whom a specific therapeutic strategy may be expected to be more successful. Finally, the rapid application of emerging clinical and biomarker strategies may reduce heterogeneity, increase trial efficiency, and, in turn, accelerate ALS drug development.
Retrospective Analysis of Adverse Drug Events Between Nafcillin Versus Cefazolin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections
Chan, Lynn, Chan-Tompkins, Noreen H., Como, James , Guarascio, Anthony J.

Mayo Clinic

Annals of Pharmacotherapy | December 31, 2019 | Volume: 54 | Issue: 7 | Pages: 662-668

10.1177/1060028019897267 | PMID 31888347 Get It

Background: Nafcillin or cefazolin are drugs of choice for methicillin-susceptible Staphylococcus aureus (MSSA) infections. Prior studies indicate a higher incidence of acute kidney injury (AKI) with nafcillin, although AKI classification and time to occurrence is not well described. Objective: To characterize the incidence and time to adverse drug events for nafcillin versus cefazolin in the inpatient setting. Methods: A retrospective cohort study evaluated hospitalized, adult patients receiving intravenous nafcillin or cefazolin for treatment of MSSA infection. Incidence and time to AKI based on RIFLE criteria were measured. Secondary end points included antibiotic discontinuation and incidence of neutropenia, thrombocytopenia, elevated transaminases, and Clostridioides difficile infection (CDI). Results: Of 324 patients who received nafcillin (n = 119) or cefazolin (n = 205), higher rates of AKI were found for nafcillin versus cefazolin (19% vs 2%, respectively; P < 0.0001). Median time to AKI with nafcillin was 6.5 days (range, 3-14 days). The majority of patients were classified as RIFLE “Risk” stratum. Nafcillin treatment discontinuations were more frequent than for cefazolin (17.6% vs 0.9%, respectively; P < 0.0001). Nafcillin was an independent predictor of AKI (odds ratio = 12.4; 95% CI = 4.14-47.60, P < 0.0001). No differences in neutropenia, thrombocytopenia, elevated transaminases, or CDI were observed. Conclusion and Relevance: Nafcillin displayed higher rates of AKI at a median of 1 week of therapy, which provides a framework for clinician monitoring and consideration of antibiotic modification. Most patients developed “Risk” class AKI (RIFLE classification), which may be reversible with prompt intervention.
The essential skill of ECG interpretation: How do we define and improve competency?
Kashou, Anthony H. , May, Adam M. , DeSimone, Christopher P., Kashou, Anthony , May, Adam, May, Adam M , DeSimone, Christopher, Noseworthy, Peter A.

Mayo Clinic

Postgraduate Medical Journal | December 24, 2019 | Volume: 96 | Issue: 1133 | Pages: 125-127

10.1136/postgradmedj-2019-137191 | PMID 31874907 Get It

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer
Bradley, Jeffrey D. , Hu, Chen , Blumenschein, George R. , Bogart, Jeffrey A. , Forster, Kenneth, Magliocco, Anthony M., Kavadi, Vivek S. , Narayan, Samir , Iyengar, Puneeth , Robinson, Clifford G. , Wynn, Raymond B. , Koprowski, Christopher D. , Olson, Michael R., Meng, Joanne, Paulus, Rebecca , Curran, Walter J. , Choy, Hak, Schild, Steven E. , Robinson, Clifford , Bradley, Jeffrey , Paulus, Rebecca , Komaki, Ritsuko , Masters, Gregory A. , Olson, Michael R.

Mayo Clinic

Journal of Clinical Oncology | December 16, 2019 | Volume: 38 | Issue: 7 | Pages: 706-714

10.1200/jco.19.01162 | PMID 31841363 Get It

PURPOSE RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non–small-cell lung cancer (NSCLC). METHODS The study used a 2 × 2 factorial design with radiation dose as 1 factor and cetuximab as the other, with a primary end point of overall survival (OS). RESULTS Median follow-up was 5.1 years. There were 3 grade 5 adverse events (AEs) in the SD arm and 9 in the HD arm. Treatment-related grade ≥3 dysphagia and esophagitis occurred in 3.2% and 5.0% of patients in the SD arm v 12.1% and 17.4% in the HD arm, respectively ( P = .0005 and < .0001). There was no difference in pulmonary toxicity, with grade ≥3 AEs in 20.6% and 19.3%. Median OS was 28.7 v 20.3 months ( P = .0072) in the SD and HD arms, respectively, 5-year OS and progression-free survival (PFS) rates were 32.1% and 23% and 18.3% and 13% ( P = .055), respectively. Factors associated with improved OS on multivariable analysis were standard radiation dose, tumor location, institution accrual volume, esophagitis/dysphagia, planning target volume and heart V5. The use of cetuximab conferred no survival benefit at the expense of increased toxicity. The prior signal of benefit in patients with higher H scores was no longer apparent. The progression rate within 1 month of treatment completion in the SD arm was 4.6%. For comparison purposes, the resultant 2-year OS and PFS rates allowing for that dropout rate were 59.6% and 30.7%, respectively, in the SD arms. CONCLUSION A 60-Gy radiation dose with concurrent chemotherapy should remain the standard of care, with the OS rate being among the highest reported in the literature for stage III NSCLC. Cetuximab had no effect on OS. The 2-year OS rates in the control arm are similar to the PACIFIC trial.
The VT Prediction Model: A simplified means to differentiate wide complex tachycardias
May, Adam M. , Kashou, Anthony H. , Sridhar, Haarini , Hodge, David O. , Carter, Rickey E. , Lin, Grace , Asirvatham, Samuel J. , Noseworthy, Peter A. , Deshmukh, Abhishek , Carter, Rickey, Asirvatham, Samuel J , Noseworthy, Peter A , Deshmukh, Abhishek J , Carter, Rickey E , May, Adam M , DeSimone, Christopher V.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | December 16, 2019 | Volume: 31 | Issue: 1 | Pages: 185-195

10.1111/jce.14321 | PMID 31840870 Get It

AbstractBackgroundThe accurate separation of undifferentiated wide complex tachycardias (WCTs) into ventricular tachycardia (VT) or supraventricular wide complex tachycardia (SWCT) using conventional, manually‐applied 12‐lead electrocardiogram (ECG) interpretation methods is difficult.PurposeWe sought to devise a new WCT differentiation method that operates solely on automated measurements routinely provided by computerized ECG interpretation software.MethodsIn a two‐part analysis, we developed and validated a logistic regression model (ie, VT Prediction Model) that utilizes routinely available computerized measurements derived from patients' paired WCT and baseline ECGs.ResultsThe derivation cohort consisted of 601 paired WCT (273 VT, 328 SWCT) and baseline ECGs from 421 patients. The VT Prediction Model, composed of WCT QRS duration (ms) (P < .0001), QRS duration change (ms) (P < .0001), QRS axis change (°) (P < .0001) and T axis change (°) (P < .0001), yielded effective VT and SWCT differentiation (area under the curve [AUC]: 0.924; confidence interval [CI]: 0.903‐0.944) for the derivation cohort. The validation cohort comprised 241 paired WCT (97 VT, 144 SWCT) and baseline ECGs from 177 patients. The VT Prediction Model's implementation on the validation cohort yielded effective WCT differentiation (AUC: 0.900; CI: 0.862‐0.939) with overall accuracy, sensitivity, and specificity of 85.0%, 80.4%, and 88.2%, respectively.ConclusionThe VT Prediction Model is an example of how readily available ECG measurements may be used to distinguish VT and SWCT effectively. Further study is needed to develop and refine newer WCT differentiation approaches that utilize computerized measurements provided by ECG interpretation software.
Whole Exome Sequencing of Highly Aggregated Lung Cancer Families Reveals Linked Loci for Increased Cancer Risk on Chromosomes 12q, 7p, and 4q
Musolf, Anthony M. , Moiz, Bilal A., Sun, Haiming , Pikielny, Claudio W. , Bossé, Yohan , Mandal, Diptasri , Andrade, Mariza de , Gaba, Colette , Li, Yafang , You, Ming , Govindan, Ramaswamy , Wilson, Richard K., Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Pinney, Susan M. , Bailey‐Wilson, Joan E. , de Andrade, Mariza , Wilson, Richard K , Amos, Christopher I , Bossé, Yohan , Pinney, Susan M , Govindan, Ramaswamy , Yang, Ping , Amos, Christopher I.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 11, 2019 | Volume: 29 | Issue: 2 | Pages: 434-442

10.1158/1055-9965.epi-19-0887 | PMID 31826912 Get It

Abstract Background: Lung cancer kills more people than any other cancer in the United States. In addition to environmental factors, lung cancer has genetic risk factors as well, though the genetic etiology is still not well understood. We have performed whole exome sequencing on 262 individuals from 28 extended families with a family history of lung cancer. Methods: Parametric genetic linkage analysis was performed on these samples using two distinct analyses—the lung cancer only (LCO) analysis, where only patients with lung cancer were coded as affected, and the all aggregated cancers (AAC) analysis, where other cancers seen in the pedigree were coded as affected. Results: The AAC analysis yielded a genome-wide significant result at rs61943670 in POLR3B at 12q23.3. POLR3B has been implicated somatically in lung cancer, but this germline finding is novel and is a significant expression quantitative trait locus in lung tissue. Interesting genome-wide suggestive haplotypes were also found within individual families, particularly near SSPO at 7p36.1 in one family and a large linked haplotype spanning 4q21.3-28.3 in a different family. The 4q haplotype contains potential causal rare variants in DSPP at 4q22.1 and PTPN13 at 4q21.3. Conclusions: Regions on 12q, 7p, and 4q are linked to increased cancer risk in highly aggregated lung cancer families, 12q across families and 7p and 4q within a single family. POLR3B, SSPO, DSPP, and PTPN13 are currently the best candidate genes. Impact: Functional work on these genes is planned for future studies and if confirmed would lead to potential biomarkers for risk in cancer.
Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT)
Kashou, Anthony H. , Noseworthy, Peter A.

Mayo Clinic

Expert Opinion on Investigational Drugs | December 11, 2019 | Volume: 29 | Issue: 1 | Pages: 1-4

10.1080/13543784.2020.1703180 | PMID 31825681 Get It